Skip to main content
SpringerLink
Log in
Book cover

Twenty Years of G-CSF pp 319–333Cite as

Use of rHuG-CSF in Infectious Diseases

  • Chapter
  • First Online:

  • 942 Accesses

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

Granulocyte-colony stimulating factor (G-CSF) is an endogenous hematopoietic growth factor that induces terminal differentiation and release of neutrophils from the bone marrow [1]. G-CSF appears to play a central role in the normal host response to infection [2] and has immunomodulatory and antibiotic enhancing functions [3]. G-CSF stimulates the growth and improves the function of both normal and defective neutrophils [4–8]. G-CSF is a member of the long-chain subtype of the class 1 cytokine superfamily, which includes growth hormone, erythropoietin (EPO), interleukin-6 (IL-6), and oncostatin M [9].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME (1997) Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 20(350):855–859

    Article  Google Scholar 

  2. Dale DC, Liles WC, Summer WR, Nelson S (1995) Review: granulocyte colony-stimulating factor–role and relationships in infectious diseases. J Infect Dis 172:1061–1075

    Article  PubMed  CAS  Google Scholar 

  3. Hartung T (1999) Granulocyte colony-stimulating factor: its potential role in infectious disease. AIDS 13(Suppl 2):S3–S9

    PubMed  CAS  Google Scholar 

  4. Sato N, Kashima K, Tanaka Y, Shimizu H, Mori M (1997) Effect of granulocyte-colony stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients. Diabetes 46:133–137

    Article  PubMed  CAS  Google Scholar 

  5. Nelson S, Heyder AM, Stone J et al (2000) A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 182:970–973

    Article  PubMed  CAS  Google Scholar 

  6. Root RK, Dale DC (1999) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in non-neutropenic patients. J Infect Dis 179(Suppl 2):S342–S352

    Article  PubMed  CAS  Google Scholar 

  7. Hübel K, Engert A (2003) Granulocyte transfusion therapy for treatment of infections after cytotoxic chemotherapy. Onkologie 26:73–79

    Article  PubMed  Google Scholar 

  8. Murata A (2003) Granulocyte colony-stimulating factor as the expecting sword for the treatment of severe sepsis. Curr Pharm Des 9:1115–1120

    Article  PubMed  CAS  Google Scholar 

  9. Hübel K, Dale DC, Liles WC (2002) Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-γ. J Infect Dis 185:1490–1501

    Article  PubMed  Google Scholar 

  10. Reiber GE, Lipsky BA, Gibbons GW (1998) The burden of diabetic foot ulcers. Am J Surg 176(2A Suppl):5S–10S

    Article  PubMed  CAS  Google Scholar 

  11. Moulik PK, Mtonga R, Gill GV (2003) Amputation and mortality in new onset diabetic foot ulcers stratified by etiology. Diabetes Care 26:491–494

    Article  PubMed  Google Scholar 

  12. Lipsky BA, Berendt AR (2000) Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev 16(suppl 1):S42–S46

    Article  PubMed  Google Scholar 

  13. International Working Group on the Diabetic Foot (2003) International Consensus on the Diabetic Foot. International Diabetes Federation, CD-ROM

    Google Scholar 

  14. Korda J, Mezo R, Balint GP (2005) Treatment of musculoskeletal infections of the foot in patients with diabetes. Therapy 2:287–300

    Article  CAS  Google Scholar 

  15. Gupta S, Koirala J, Khardori R, Khardori N (2007) Infections in diabetes mellitus and hyperglycemia. Infect Dis Clin North Am 21:617–638

    Article  PubMed  Google Scholar 

  16. Sato N, Shimizu H (1993) Granulocyte-colony stimulating factor improves an impaired bactericidal function in neutrophils from STZ-induced diabetic rats. Diabetes 42:470–473

    Article  PubMed  CAS  Google Scholar 

  17. Geerlings SE, Hoepelman AI (1999) Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 26:295–365

    Article  Google Scholar 

  18. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B (1997) Impaired leucocyte functions in diabetic patients. Diabet Med 14:29–34

    Article  PubMed  CAS  Google Scholar 

  19. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J (2005) The global burden of diabetic foot disease. Lancet 366:1719–1724

    Article  PubMed  Google Scholar 

  20. Cruciani M, Lipsky BA, Mengoli C, de Lalla F (2005) Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis. Diabetes Care 28:454–460

    Article  PubMed  CAS  Google Scholar 

  21. Cruciani M, Lipsky BA, Mengoli C, de Lalla F (2009) Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database Syst Rev CD006810

    Google Scholar 

  22. Lipsky BA, Hoey C (2009) Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis 49:1541–1549

    Article  PubMed  Google Scholar 

  23. Niederman MS, Bass JB Jr, Campbell GD et al (1993) Guidelines for the initial management of adults with community acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 148:1418–1426

    PubMed  CAS  Google Scholar 

  24. Wunderink R, Leeper K Jr, Schein R et al (2001) Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 119:523–529

    Article  PubMed  CAS  Google Scholar 

  25. Cebon J, Layton JE, Maher D, Morstyn G (1994) Endogenous hemopoietic growth factors in neutropenia and infection. Br J Hematol 86:265–274

    Article  CAS  Google Scholar 

  26. Hebert JC, O’Reilly M, Gamelli RL (1990) Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg 125:1075–1078

    Article  PubMed  CAS  Google Scholar 

  27. Nelson S, Summer W, Bagby G et al (1991) Granulocyte colony stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis 164:901–906

    Article  PubMed  CAS  Google Scholar 

  28. Cheng AC, Stephens DP, Currie BJ (2007) Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev CD004400

    Google Scholar 

  29. Siempos II, Vardakas KZ, Kopterides P, Falagas ME (2008) Adjunctive therapies for community acquired pneumonia: a systematic review. J Antimicrob Chemother 62:661–668

    Article  PubMed  CAS  Google Scholar 

  30. Greenwood BM (2007) Corticosteroids for acute bacterial meningitis. N Engl J Med 357:2507–2509

    Article  PubMed  CAS  Google Scholar 

  31. Brandt CT, Lundgren JD, Lund SP et al (2004) Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis. Infect Immun 72:4647–4653

    Article  PubMed  CAS  Google Scholar 

  32. Ostergaard C, Benfield T, Gesser B et al (1999) Pretreatment with granulocyte colony-stimulating factor attenuates the inflammatory response but not the bacterial load in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Infect Immun 67:3430–3436

    PubMed  CAS  Google Scholar 

  33. Hartung T (1998) Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr Opin Hematol 5:221–225

    Article  PubMed  CAS  Google Scholar 

  34. De Lalla F, Nicolin R, Lazzarini L (2000) Safety and efficacy of recombinant granulocyte colony-stimulating factor as an adjunctive therapy for Streptococcus pneumoniae meningitis in non-neutropenic adult patients: a pilot study. J Antimicrob Chemother 46:843–846

    Article  PubMed  Google Scholar 

  35. Ruhnke M, Böhme A, Buchheidt D et al (2003) Diagnosis of invasive fungal infections in hematology and oncology – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S141–S148

    Article  PubMed  Google Scholar 

  36. Bohme A, Karthaus M (1999) Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium. Chemotherapy 45:315–324

    Article  PubMed  CAS  Google Scholar 

  37. Diamond RD (1993) Interactions of phagocytic cells with Candida and other opportunistic fungi. Arch Med Res 24:361–369

    PubMed  CAS  Google Scholar 

  38. Rodriquez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ (1998) The potential role of cytokine therapy for fungal infection in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 126:1270–1278

    Article  Google Scholar 

  39. Stevens DA (1998) Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 26:1266–1269

    Article  PubMed  CAS  Google Scholar 

  40. Roilides E, Farmaki E (2001) Granulocyte colony-stimulating factor and other cytokines in antifungal therapy. Clin Microbiol Infect 7(Suppl 2):62–67

    Article  PubMed  CAS  Google Scholar 

  41. Hazel DL, Newland AC, Kelsey SM (1999) Malignancy: granulocyte colony stimulating factor increases the efficacy of conventional amphotericin in the treatment of presumed deep-seated fungal infection in neutropenic patients following intensive chemotherapy or bone marrow transplantation for haematological malignancies. Hematology 4:305–311

    PubMed  CAS  Google Scholar 

  42. Flynn TN, Kelsey SM, Hazel DL, Guest JF (1999) Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK. Pharmacoeconomics 16:543–550

    Article  PubMed  CAS  Google Scholar 

  43. Dignani MC, Anaissie EJ, Hester JP et al (1997) Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 11:1621–1630

    Article  PubMed  CAS  Google Scholar 

  44. Ozsahin H, von Planta M, Müller I et al (1998) Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 92:2719–2724

    PubMed  CAS  Google Scholar 

  45. Girmenia C, Iori AP, Boecklin F et al (1999) Fusarium infections in patients with severe aplastic anemia: review and implications for management. Haematologica 84:114–118

    PubMed  CAS  Google Scholar 

  46. Mohammad RA (2010) Use of granulocyte colony-stimulating factor in patients with severe sepsis or septic shock. Am J Health Syst Pharm 67:1238–1245

    Article  PubMed  CAS  Google Scholar 

  47. Stephens DP, Thomas JH, Higgins A et al (2008) Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med 36:448–454

    Article  PubMed  CAS  Google Scholar 

  48. Aapro M, Crawford J, Kamioner D (2010) Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 18:529–541

    Article  PubMed  Google Scholar 

  49. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266

    Article  PubMed  Google Scholar 

  50. Pizzo PA (1999) Fever in immunocompromised patients. N Engl J Med 341:893–900

    Article  PubMed  CAS  Google Scholar 

  51. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340

    PubMed  CAS  Google Scholar 

  52. Herbst C, Naumann F, Kruse EB, Monsef I, Bohlius J, Schulz H, Engert A (2009) Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 21:CD007107

    Google Scholar 

  53. Lyman GH, Kuderer NM, Djulbegovic B (2002) Prophylactic granulocyte colony stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 112:406–411

    Article  PubMed  CAS  Google Scholar 

  54. Bohlius J, Reiser M, Schwarzer G, Engert A (2003) Impact of granulocyte colony stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 122:413–423

    Article  PubMed  CAS  Google Scholar 

  55. Bohlius J, Reiser M, Schwarzer G, Engert A (2004) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev CD003189

    Google Scholar 

  56. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Sculier JP (2002) Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 37:115–123

    Article  PubMed  CAS  Google Scholar 

  57. Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR (2004) Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 22:3350–3356

    Article  PubMed  CAS  Google Scholar 

  58. Sasse EC, Sasse AD, Brandalise S, Clark OA, Richards S (2005) Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev 3:CD004139

    Google Scholar 

  59. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L (2006) Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 24:5207–5215

    Article  PubMed  CAS  Google Scholar 

  60. Sung L, Nathan PC, Alibhai SMH, Tomlinson GA, Beyene J (2007) Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of Infection. Ann Intern Med 147:400–411

    PubMed  Google Scholar 

  61. Berghmans T, Paesmans M, Lafitte JJ et al (2002) herapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 10:181–188

    Article  PubMed  CAS  Google Scholar 

  62. Clark OAC, Lyman G, Castro AA, Clark LGO, Djulbegovic B (2003) Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 3:CD003039

    Google Scholar 

  63. Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433–2453

    Article  PubMed  CAS  Google Scholar 

  64. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–4205

    Article  PubMed  CAS  Google Scholar 

  65. Mauss S, Steinmetz HT, Willers R et al (1997) Induction of granulocyte colony-stimulating factor by acute febrile infection but not by neutropenia in HIV-seropositive individuals. J Acquir Immune Defic Syndr Hum Retrovirol 14:430–434

    Article  PubMed  CAS  Google Scholar 

  66. Keiser P, Rademacher S, Smith JW, Skiest D, Vadde V (1998) Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV infected patients. Am J Med 104:48–55

    Article  PubMed  CAS  Google Scholar 

  67. Kuritzkes DR (2000) Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 30:256–260

    Article  PubMed  CAS  Google Scholar 

  68. Pitrak DL, Tsai HC, Mullane KM, Sutton SH, Stevens P (1996) Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome. J Clin Invest 98:2714–2719

    Article  PubMed  CAS  Google Scholar 

  69. Laursen AL, Rungby J, Andersen PL (1885) Decreased activation of the respiratory burst in neutrophils from AIDS patients with previous Pneumocystis carinii pneumonia. J Infect Dis 172:497–505

    Article  Google Scholar 

  70. Hermans P (1999) HIV disease-related neutropenia: an independent risk factor for severe infections. AIDS 13(Suppl 2):S11–S17

    PubMed  Google Scholar 

  71. Moore DA, Benepal T, Portsmouth S, Gill J, Gazzard BG (2001) Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study. Clin Infect Dis 32:469–475

    Article  PubMed  CAS  Google Scholar 

  72. Kuritzkes DR, Parenti D, Ward DJ et al (1998) Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. AIDS 12:65–74

    Article  PubMed  CAS  Google Scholar 

  73. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2009) Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58(RR04):1–198

    Google Scholar 

  74. Stoll BJ, Gordon T, Korones SB et al (1996) Late-onset sepsis in very low birthweight neonates: a report from the National Institute of Child Health and Human Development neonatal research network. J Pediatr 129:63–71

    Article  PubMed  CAS  Google Scholar 

  75. Carr R, Modi N (1997) Haemopoietic colony stimulating factors for preterm neonates. Arch Dis Child Fetal Neonatal Ed 76:F128–F133

    Article  PubMed  CAS  Google Scholar 

  76. Damman O, Leviton A (1998) Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant. Semin Pediatr Neurol 5:190–201

    Article  Google Scholar 

  77. Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O’Shea TM (1999) Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. Pediatrics 104:1345–1350

    Article  PubMed  CAS  Google Scholar 

  78. Bedford Russell AR, Emmerson AJ, Wilkinson N et al (2001) A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birth weight infants with presumed sepsis and neutropenia. Arch Dis Child Fetal Neonatal Ed 84:F172–F176

    Article  PubMed  CAS  Google Scholar 

  79. Gessler P, Lüders R, König S, Haas N, Lasch P, Kachel W (1995) Neonatal neutropenia in low birthweight premature infants. Am J Perinatol 12:34–38

    Article  PubMed  CAS  Google Scholar 

  80. Engle WD, Rosenfeld CR (1984) Neutropenia in high risk neonates. J Pediatr 105:982–986

    Article  PubMed  CAS  Google Scholar 

  81. Koenig JH, Christensen RD (1989) Incidence, neutrophil kinetics and natural history of neonatal neutropenia associated with maternal hypertension. N Engl J Med 321:557–562

    Article  PubMed  CAS  Google Scholar 

  82. Rodwell RL, Taylor KMCD, Tudehope DI, Gray PH (1993) Hematologic scoring system in early diagnosis of sepsis in neutropenic newborns. Pediatr Infect Dis J 12:372–376

    Article  PubMed  CAS  Google Scholar 

  83. Christensen RD (1989) Neutrophil kinetics in the fetus and neonate. Am J Pediatr Hematol Oncol 11:215–223

    PubMed  CAS  Google Scholar 

  84. Carr R (2000) Neutrophil production and function in newborn infants. Br J Haematol 110:18–28

    Article  PubMed  CAS  Google Scholar 

  85. Hill HR (1987) Biochemical, structural, and functional abnormalities of polymorphonuclear leukocytes in the neonate. Pediatr Res 22:375–382

    Article  PubMed  CAS  Google Scholar 

  86. Carr R, Huizinga TWJ (2000) Low soluble FcRIII demonstrates reduced neutrophil reserves in preterm neonates. Arch Dis Child Fetal Neonatal Ed 83:F160

    Article  PubMed  CAS  Google Scholar 

  87. Gillan ER, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS (1994) A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 84:1427–1433

    PubMed  CAS  Google Scholar 

  88. Cairo MS, Christensen RD, Sender LS et al (1995) Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birth weight neonates: significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils. Blood 86:2509–2515

    PubMed  CAS  Google Scholar 

  89. Kuhn P, Messer J, Paupe A et al (2009) A multicenter, randomized, placebo-controlled trial of prophylactic recombinant granulocyte-colony stimulating factor in preterm neonates with neutropenia. J Pediatr 155:324–330

    Article  PubMed  CAS  Google Scholar 

  90. Carr R, Brocklehurst P, Doré CJ, Modi N (2009) Granulocyte-macrophage colony-stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Lancet 373:226–233

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical and Surgical Science, Section of Dermatology and Venereology, University of Verona, Verona, 37126, Italy

    Letizia Leone

  2. Center of Community Medicine, Infectious Diseases Treatment and Surveillance Unit, Verona, and Infectious Diseases Service, G. Fracastoro Hospital, ULSS 20 Verona, Via Germania, 20, Verona, 37135, Italy

    Mario Cruciani

Authors
  1. Letizia Leone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mario Cruciani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario Cruciani .

Editor information

Editors and Affiliations

  1. Amgen Inc., One Amgen Center Drive, Thousand Oaks, 91320, California, USA

    Graham Molineux

  2. MA Foote Associates, Par Five Court 4284, Westlake Village, 91362, California, USA

    MaryAnn Foote

  3. Amgen, Inc., One Amgen Center Dr. 1, Thousand Oaks, 91320, California, USA

    Tara Arvedson

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Basel AG

About this chapter

Cite this chapter

Leone, L., Cruciani, M. (2012). Use of rHuG-CSF in Infectious Diseases. In: Molineux, G., Foote, M., Arvedson, T. (eds) Twenty Years of G-CSF. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0348-0218-5_17

Download citation

Publish with us

Policies and ethics

Search

Navigation